Article Text

Download PDFPDF

The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice
  1. Sara M Mangsbo1,
  2. Niina Veitonmäki2,
  3. Erika Gustfson1,
  4. Karin Enell Smith2,
  5. Christina Furebring2,
  6. Per Norlén2,
  7. Malin Lindstedt3,
  8. Thomas H Tötterman1 and
  9. Peter Ellmark2
  1. Aff1 grid.8993.b0000000419369457Immunology, Genetics and PathologyIGP, Uppsala University Uppsala Sweden
  2. Aff2 grid.432080.dAlligator Bioscience AB Lund Sweden
  3. Aff3 grid.4514.40000000109302361ImmunotechnologyLund University Sweden

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Local activation of costimulatory pathways by e.g. CD40 activation has been shown to generate powerful systemic anti-tumor responses. Here we report significant anti-tumor effects obtained with an optimized fully human agonistic CD40 antibody, ADC-1013, in two syngeneic tumor models.

An hCD40 transgenic mouse (hCD40tg) strain was used to evaluate the immune mediated anti-tumor effects of ADC-1013. Dendritic cells obtained from hCD40tg mice were hCD40 positive and could be activated by stimulation with ADC-1013 to a similar extent as human monocyte derived dendritic cells. Furthermore, stimulation of dendritic cells from hCD40tg mice in vitro, with ADC-1013, induced antigen specific T cell activation.

Two different syngeneic tumor models, hCD40 negative MB49 bladder cancer and hCD40 positive B16.F10.hCD40+ melanoma, was used to demonstrate anti-tumor effects. Subcutaneous tumors from both models were characterized by flow cytometry and immunohistochemistry in hCD40tg mice. Treatment of the bladder cancer model (MB49) with ADC-1013 resulted in significant anti-tumor response and long term tumor immunity. The anti-tumor immunity was shown to be T cell dependent and naïve mice were protected from tumor challenge by transplantation of splenocytes from cured hCD40tg mice. In addition, significant anti-tumor effect was demonstrated in a subcutaneous B16.F10.hCD40+ melanoma model.

The human CD40 agonistic antibody ADC-1013 is the first costimulatory antibody optimized for local immunotherapy of cancer. Strong immune mediated anti-tumor effects were demonstrated. ADC-1013 is currently in late pre-clinical development.